Inflammation in atherosclerosis, Nature, vol.103, issue.6917, pp.868-874, 2002. ,
DOI : 10.1074/jbc.274.45.32048
Platelet-Leukocyte Interactions in Inflammation and Atherothrombosis, Seminars in Thrombosis and Hemostasis, vol.33, issue.2, pp.123-127, 2007. ,
DOI : 10.1055/s-2007-969023
Inflammation, Immunity, and Hypertension, Hypertension, vol.57, issue.2, pp.132-140, 2011. ,
DOI : 10.1161/HYPERTENSIONAHA.110.163576
URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3028593
Epoxyeicosatrienoic acids and endothelium-dependent responses. Pflugers Arch, pp.881-895, 2010. ,
DOI : 10.1007/s00424-010-0804-6
URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3373596
Vascular Pharmacology of Epoxyeicosatrienoic Acids, Adv. Pharmacol, vol.60, pp.27-59, 2010. ,
DOI : 10.1016/B978-0-12-385061-4.00002-7
URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3373307
HIGH VERSUS STANDARD CLOPIDOGREL MAINTENANCE DOSE AFTER PERCUTANEOUS CORONARY INTERVENTION AND EFFECTS ON PLATELET INHIBITION, ENDOTHELIAL FUNCTION, AND INFLAMMATION. RESULTS OF THE ARMYDA-150 MG (ANTIPLATELET THERAPY FOR REDUCTION OF MYOCARDIAL DAMAGE DURING ANGIOPLASTY) RANDOMIZED STUDY, Rational Pharmacotherapy in Cardiology, vol.7, issue.5, pp.771-778, 2011. ,
DOI : 10.20996/1819-6446-2011-7-5-644-652
URL : http://doi.org/10.1016/j.jacc.2010.09.050
Clopidogrel, American Journal of Cardiovascular Drugs, vol.71, issue.3, pp.361-374, 2012. ,
DOI : 10.1067/mcp.2002.122018
Pharmacodynamic properties of antiplatelet agents: current knowledge and future perspectives, Expert Review of Clinical Pharmacology, vol.366, issue.3, pp.319-336, 2012. ,
DOI : 10.1056/NEJMoa1200933
Clopidogrel Pharmacogenetics and Its Clinical Implications, American Journal of Therapeutics, vol.17, issue.3, pp.66-73, 2010. ,
DOI : 10.1097/MJT.0b013e3181afbf62
Cytochrome P-450 polymorphisms and response to clopidogrel, N. Engl. J. Med, vol.360, pp.2250-2251, 2009. ,
Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects, Blood, vol.108, issue.7, pp.2244-2247, 2006. ,
DOI : 10.1182/blood-2006-04-013052
Influence of CYP2C19 and CYP3A4 gene polymorphisms on clopidogrel responsiveness in healthy subjects, Journal of Thrombosis and Haemostasis, vol.5, issue.10, pp.2153-2155, 2007. ,
DOI : 10.1016/S0140-6736(03)12516-0
Role of the P2Y12 gene polymorphism in platelet responsiveness to clopidogrel in healthy subjects, Journal of Thrombosis and Haemostasis, vol.84, issue.9, pp.2096-2097, 2006. ,
DOI : 10.1161/01.CIR.0000130846.46168.03
Clopidogrel increases expression of chemokines in peripheral blood mononuclear cells in patients with coronary artery disease: Results of a double-blind placebo-controlled study, J. Thromb. Haemost, vol.4, pp.2140-2147, 2006. ,
A randomised study comparing the antiplatelet and antiinflammatory effect of clopidogrel 150 mg/day versus 75 mg/day in patients with ST-segment elevation acute myocardial infarction and poor responsiveness to clopidogrel: Results from the DOUBLE study, Thromb. Res, vol.125, pp.309-314, 2010. ,
Lack of evidence for pleiotropic effects of clopidogrel on endothelial function and inflammation in patients with stable coronary artery disease: Results of the double-blind, randomized CASSANDRA study, Clin. Res. Cardiol, vol.100, pp.29-36, 2011. ,
Changes in Inflammatory Biomarkers in Patients Treated With Ticagrelor or Clopidogrel, Clinical Cardiology, vol.20, issue.4, pp.206-212, 2010. ,
DOI : 10.1161/01.CIR.99.16.2079
A randomized comparison of the effects of aspirin and clopidogrel on thrombotic risk factors and C-reactive protein following myocardial infarction: the CADET trial, Journal of Thrombosis and Haemostasis, vol.345, issue.11, 1934. ,
DOI : 10.1111/j.1365-2362.1994.tb02373.x
Effect of antiplatelet therapy on inflammatory markers in atherothrombotic patients, Thrombosis and Haemostasis, vol.103, issue.1, pp.71-82, 2010. ,
DOI : 10.1160/TH09-03-0177
Genetic Polymorphism of CYP2C19 Gene in the Stanislas Cohort. A link with Inflammation, Annals of Human Genetics, vol.348, issue.2, pp.178-183, 2008. ,
DOI : 10.1161/01.CIR.101.15.1767
The -50G>T Polymorphism in the Promoter of the CYP2J2 Gene in Coronary Heart Disease: The Ludwigshafen Risk and Cardiovascular Health Study, Clinical Chemistry, vol.53, issue.3, pp.539-540, 2007. ,
DOI : 10.1373/clinchem.2006.084756
Common polymorphisms in CYP2C9, subclinical atherosclerosis and risk of ischemic vascular disease in 52???000 individuals, The Pharmacogenomics Journal, vol.271, issue.5, pp.327-332, 2009. ,
DOI : 10.1161/hh2101.099268
Applying Platelet Function Testing in Clinical Practice, JAMA, vol.306, issue.11, pp.1260-1261, 2011. ,
DOI : 10.1001/jama.2011.1349
Identification of low responders to a 300-mg clopidogrel loading dose in patients undergoing coronary stenting, Thromb. Res, vol.115, pp.101-108, 2005. ,
Clopidogrel for Coronary Stenting: Response Variability, Drug Resistance, and the Effect of Pretreatment Platelet Reactivity, Circulation, vol.107, issue.23, pp.2908-2913, 2003. ,
DOI : 10.1161/01.CIR.0000072771.11429.83
Drug Insight: clopidogrel nonresponsiveness, Nature Clinical Practice Cardiovascular Medicine, vol.354, issue.7, pp.387-395, 2006. ,
DOI : 10.1038/ncpcardio0602
Prevalence of clopidogrel non-responders among patients with stable angina pectoris scheduled f or elective coronary stent placement, Thromb. Haemost, vol.89, pp.783-787, 2003. ,
Platelets in inflammation and atherogenesis, Journal of Clinical Investigation, vol.115, issue.12, pp.3378-3384, 2005. ,
DOI : 10.1172/JCI27196
Impact of inflammatory markers on platelet inhibition and cardiovascular outcome including stent thrombosis in patients with symptomatic coronary artery disease, Atherosclerosis, vol.213, issue.1, pp.256-262, 2010. ,
DOI : 10.1016/j.atherosclerosis.2010.07.023
Clopidogrel, but not abciximab, reduces platelet leukocyte conjugates and P-selectin expression in a human ex vivo in vitro model, Clinical Pharmacology & Therapeutics, vol.71, issue.3, pp.176-185, 2002. ,
DOI : 10.1067/mcp.2002.122018
Unlike Gemfibrozil, Clopidogrel Glucuronide is not a Potent Inhibitior of CYP2C8, Available, vol.online, 2007. ,
Effect of an increased clopidogrel maintenance dose or lansoprazole co-administration on the antiplatelet response to clopidogrel in CYP2C19-genotyped healthy subjects, Journal of Thrombosis and Haemostasis, vol.119, issue.3, pp.610-613, 2010. ,
DOI : 10.1161/CIRCULATIONAHA.108.857722
Adenosine Diphosphate-Induced Platelet Aggregation Is Associated With P2Y12 Gene Sequence Variations in Healthy Subjects, Circulation, vol.108, issue.8, pp.989-995, 2003. ,
DOI : 10.1161/01.CIR.0000085073.69189.88
URL : http://circ.ahajournals.org/content/circulationaha/108/8/989.full.pdf